Laboratory workup for osteoporosis: Which tests are most cost-effective?

Postgraduate Medicine

Volumn 114, Issue 3, 2003, Pages 35-44

  Crandall, Carolyn ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; CALCIUM; GLUCOCORTICOID; GONADORELIN ANTAGONIST; HEPARIN; PHENOBARBITAL; PHENYTOIN; THYROID HORMONE; THYROTROPIN; THYROXINE; VITAMIN D;

BONE DENSITY; BONE MASS; CELIAC DISEASE; CLINICAL PRACTICE; CONFERENCE PAPER; COST; COST EFFECTIVENESS ANALYSIS; CUSHING DISEASE; DIAGNOSTIC IMAGING; DIET RESTRICTION; DRUG EXPOSURE; HORMONE SUBSTITUTION; HUMAN; HYPERCALCIURIA; HYPERTHYROIDISM; HYPOGONADISM; LABORATORY TEST; MALABSORPTION; MENOPAUSE; ORGANIZATION; OSTEOPOROSIS; PAGET BONE DISEASE; PARATHYROID HORMONE BLOOD LEVEL; POSTMENOPAUSE; PRACTICE GUIDELINE; PREMENOPAUSE; PREVALENCE; SCREENING; THYROTROPIN BLOOD LEVEL; THYROXINE BLOOD LEVEL; URINALYSIS; VITAMIN BLOOD LEVEL; VITAMIN D DEFICIENCY; WORLD HEALTH ORGANIZATION;

EID: 0141595328     PISSN: 00325481     EISSN: None     Source Type: Journal    
DOI: 10.3810/pgm.2003.09.1492     Document Type: Conference Paper

References (14)

1. Hodgson SF, Watts NB, Bilezikian JP, et al. American Association of Clinical Endocrinologists 2001 Medical Guidelines for Clinical Practice for the Prevention and Management of Postmenopausal Osteoporosis. Endocr Pract 2001;7(4):293-312
2. Management of postmenopausal osteoporosis: position statement of the North American Menopause Society. Menopause 2002;9(2):84-101
3. National Osteoporosis Foundation. Physician's guide to prevention and treatment of osteoporosis. Washington, DC: National Osteoporosis Foundation, 1999
4. American Medical Association. Managing osteoporosis. Part one: detection and clinical issues in testing. Chicago: American Medical Association, 1999
5. American Medical Assocation. Managing osteoporosis. Part four: update in patient management. Chicago: American Medical Association, 2001
6. Osteoporosis prevention, diagnosis, and therapy. JAMA 2001;285(6):785-95
7. Screening for osteoporosis in postmenopausal women: recommendations and rationale. Ann Intern Med 2002;137(6):526-8
8. Brown JP, Josse RG. 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. Can Med Assoc J 2002;167 (10 Suppl):S1-34
9. Tannenbaum C, Clark J, Schwartzman K, et al. Yield of laboratory testing to identify secondary contributors to osteoporosis in otherwise healthy women. J Clin Endocrinol Metab 2002;87(10):4431-7
10. Johnson BE, Lucasey B, Robinson RG, et al. Contributing diagnoses in osteoporosis: the value of a complete medical evaluation. Arch Intern Med 1989;149(5):1069-72
11. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organ Tech Rep Ser 1994;843:1-129
12. Kiebzak GM, Beinart GA, Perser K, et al. Undertreatment of osteoporosis in men with hip fracture. Arch Intern Med 2002;162(19):2217-22
13. Gardner MJ, Flik KR, Mooar P, et al. Improvement in the undertreatment of osteoporosis following hip fracture. J Bone Joint Surg Am 2002;84-A(8):1342-8
14. Hajcsar EE, Hawker G, Bogoch ER. Investigation and treatment of osteoporosis in patients with fragility fractures. Can Med Assoc J 2000;163(7):819-22